Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Study Phase : Approved
Sponsor : Yifan Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
LG Chem enters Chinese osteoarthritis treatment market
Details : Hyruan One (hyaluronic acid) is a small molecule, dihydrofolate reductase inhibitor, given intra-articularly. It is China’s first single-injection osteoarthritis treatment.
Brand Name : Hyruan One
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 03, 2024
Lead Product(s) : Hyaluronic Acid
Therapeutic Area : Musculoskeletal
Highest Development Status : Approved
Sponsor : Yifan Pharmaceutical
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LB-LR1109
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Aveo Oncology
Deal Size : Not Applicable
Deal Type : Not Applicable
LG Chem and AVEO Start Phase 1 Anti-Cancer Compound Study
Details : LB-LR1109, an anti-cancer investigational drug, works by modulationg LILRB1, it is being investigated in unresectable and metastatic non-small cell lung cancer, renal cell carcinoma, etc.
Brand Name : LB-LR1109
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 13, 2024
Lead Product(s) : LB-LR1109
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Aveo Oncology
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LB54640
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Rhythm Pharmaceuticals
Deal Size : $305.0 million
Deal Type : Licensing Agreement
Rhythm Acquires Global Rights To Oral MC4R Agonist LB54640
Details : Under the agreement, Rhythm will acquire global rights for LB54640, an investigational oral small molecule MC4R agonist now in Phase 2 trials for patients with acquired hypothalamic obesity.
Brand Name : LB54640
Molecule Type : Small molecule
Upfront Cash : $100.0 million
January 04, 2024
Lead Product(s) : LB54640
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Rhythm Pharmaceuticals
Deal Size : $305.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Sabin Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : UNICEF
Deal Size : $200.0 million
Deal Type : Agreement
LG Chem to Supply UNICEF with $200 Million Worth of Essential Vaccines
Details : Under the terms of the agreement, LG Chem will supply UNICEF with its polio vaccine Eupolio and a pentavalent vaccine Eupenta that prevents diphtheria, pertussis, tetanus, hepatitis B and meningitis to solve global public health issues.
Brand Name : Eupolio
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 14, 2023
Lead Product(s) : Sabin Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : UNICEF
Deal Size : $200.0 million
Deal Type : Agreement
Lead Product(s) : Tigulixostat
Therapeutic Area : Rheumatology
Study Phase : Phase III
Sponsor : Innovent Biologics
Deal Size : $95.5 million
Deal Type : Collaboration
Details : LC350189 (tigulixostat) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.
Brand Name : LC350189
Molecule Type : Small molecule
Upfront Cash : $10.0 million
December 14, 2022
Lead Product(s) : Tigulixostat
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Sponsor : Innovent Biologics
Deal Size : $95.5 million
Deal Type : Collaboration
Lead Product(s) : Tivozanib
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : Aveo Oncology
Deal Size : $566.0 million
Deal Type : Acquisition
LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash
Details : AVEO will establish LG Chem’s commercial presence in oncology through AVEO’s lead product, FOTIVDA® (tivozanib), which received U.S. FDA approval for the treatment of relapsed or refractory advanced renal cell carcinoma following two or more prior s...
Brand Name : Fotivda
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 18, 2022
Lead Product(s) : Tivozanib
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Aveo Oncology
Deal Size : $566.0 million
Deal Type : Acquisition
Lead Product(s) : Tigulixostat
Therapeutic Area : Rheumatology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LG Chem Enters Final Stage of Clinical Development for New Gout Drug
Details : Results from US Phase 2 clinical trial—primary end point set at a challenging level confirmed the potential of LC350189 (tigulixostat) as a new gout treatment distinguished from pre-existing drugs, while also demonstrating safety similar to that of the...
Brand Name : LC350189
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2022
Lead Product(s) : Tigulixostat
Therapeutic Area : Rheumatology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LG203003
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LG Chem Announces First Subject Enrolled in Phase 1 Clinical Trial of NASH New Drug
Details : LG203003 is second NASH compound is formulated to suppress the accumulation of fat in liver cells by selectively impeding the activation of DGAT2 (diacylglycerol O-acyltransferase 2), a triglyceride synthetase, thus reducing liver cell damage.
Brand Name : LG203003
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 14, 2022
Lead Product(s) : LG203003
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : LR19023
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : MaxCyte
Deal Size : Undisclosed
Deal Type : Licensing Agreement
MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs
Details : LG Chem is strengthening its anti-cancer sector through advanced construction of cell drug platform technologies. LR19023, the next-generation CAR-T cell treatment, is currently in the pre-clinical stage and under development as a solid cancer therapeuti...
Brand Name : LR19023
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 12, 2022
Lead Product(s) : LR19023
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : MaxCyte
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : PD-L1 XT
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Avacta Group
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
LG Chem Renews License Triggering Payment to Avacta
Details : Under the terms of the agreement, LG Chem has the exclusive rights to develop and commercialise, on a global basis, Avacta’s Affimer® PD-L1 inhibitor (PD-L1 XT) with Affimer XT™ serum half-life extension for a range of indications.
Brand Name : PD-L1 XT
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 30, 2022
Lead Product(s) : PD-L1 XT
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Avacta Group
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
LOOKING FOR A SUPPLIER?